{
    "info": {
        "nct_id": "NCT03740529",
        "official_title": "A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)",
        "inclusion_criteria": "* Histologically confirmed CLL/SLL, WM, or NHL intolerant to either ≥ 2 prior standard of care regimens given in combination or sequentially OR have received 1 prior BTK inhibitor-containing regimen when a BTK inhibitor is approved as first line therapy (Phase 1) OR with prior treatment defined by phase 2 cohort (Phase 2 Patients only).\n* Adequate hematologic function (Phase 1 and 1b Patients only).\n* Responsive to transfusion support if given for thrombocytopenia or anemia (Phase 1 and 1b Patients only).\n* Histologically confirmed relapsed/recurrent CLL in whom venetoclax is appropriate standard salvage treatment; no prior venetoclax is permitted (Phase 1b Arm A Patients only).\n* Histologically confirmed relapsed/refractory CLL in whom venetoclax + rituximab is appropriate standard salvage treatment; no prior venetoclax is permitted (Phase 1b Arm B Patients only).\n* Eastern Cooperative Oncology Group (ECOG) 0-2.\n* Adequate hepatic and renal function.\n* Ability to receive study drug therapy orally.\n* Willingness of men and women of reproductive potential (defined as following menarche and not postmenopausal [and 2 years of non-therapy-induced amenorrhea] or surgically sterile) to observe conventional and effective birth control.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Investigational agent or anticancer therapy within 5 half-lives or 14 days, whichever is shorter, prior to planned start of specified study therapy except antineoplastic and immunosuppressant monoclonal antibody treatment must be discontinued a minimum of 4 weeks prior to the first dose of pirtobrutinib. In addition, no concurrent systemic anticancer therapy is permitted.\n* Major surgery within 4 weeks prior to planned start of specified study therapy.\n* Radiotherapy with a limited field of radiation for palliation within 7 days of the first dose of study treatment.\n* Pregnancy or lactation.\n* Patients requiring therapeutic anticoagulation with warfarin.\n* Any unresolved toxicities from prior therapy greater than CTCAE (version 5.0) Grade 2 or greater at the time of starting study treatment except for alopecia.\n* History of allogeneic or autologous stem cell transplant (SCT) or chimeric antigen receptor-modified T-cell (CAR-T) therapy within the past 60 days (180 days before the PK trigger) prior to planned start of specified study therapy.\n* Known central nervous system (CNS) involvement by systemic lymphoma. Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of disease may be eligible and enrolled to phase 2 Cohort 7 if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval.\n* Active uncontrolled auto-immune cytopenia where new therapy introduced or concomitant therapy escalated within the 4 weeks prior to study enrollment is required to maintain adequate blood counts.\n* Clinically significant, uncontrolled cardiac, cardiovascular disease or history of myocardial infarction within 6 months prior to planned start of pirtobrutinib.\n* Active uncontrolled systemic bacterial, viral, fungal or parasitic infection.\n* Patients who have tested positive for human immunodeficiency virus (HIV) are excluded. For patients with unknown HIV status, HIV testing will be performed at Screening and result should be negative for enrollment.\n* Clinically significant active malabsorption syndrome.\n* Current treatment with certain strong CYP3A4 inhibitors or inducers and/or strong P-gp inhibitors.\n* For patients enrolled to phase 1b Arm A or B: Patients with prior treatment with venetoclax or other BCL-2 inhibitors.\n* Prior treatment with pirtobrutinib.\n* Active second malignancy unless in remission and with life expectancy > 2 years.\n* Known hypersensitivity to any component or excipient of pirtobrutinib.\n* For patients enrolled to phase 1b Arm B: Patients with prior significant hypersensitivity, allergy, or anaphylactic reaction to rituximab/biosimilar requiring discontinuation.\n* Patients with prior significant hypersensitivity to rituximab requiring discontinuation, prior allergic or anaphylactic reaction to rituximab (Phase 1b Arm B Patients only).",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Histologically confirmed CLL/SLL, WM, or NHL intolerant to either ≥ 2 prior standard of care regimens given in combination or sequentially OR have received 1 prior BTK inhibitor-containing regimen when a BTK inhibitor is approved as first line therapy (Phase 1) OR with prior treatment defined by phase 2 cohort (Phase 2 Patients only).",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed CLL/SLL, WM, or NHL",
                    "criterion": "diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "disease subtype",
                            "expected_value": [
                                "CLL/SLL",
                                "WM",
                                "NHL"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "intolerant to either ≥ 2 prior standard of care regimens given in combination or sequentially",
                    "criterion": "treatment intolerance",
                    "requirements": [
                        {
                            "requirement_type": "number of prior standard of care regimens",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "regimens"
                            }
                        },
                        {
                            "requirement_type": "treatment sequence",
                            "expected_value": [
                                "combination",
                                "sequentially"
                            ]
                        },
                        {
                            "requirement_type": "intolerance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "have received 1 prior BTK inhibitor-containing regimen when a BTK inhibitor is approved as first line therapy (Phase 1)",
                    "criterion": "prior BTK inhibitor-containing regimen",
                    "requirements": [
                        {
                            "requirement_type": "number of prior BTK inhibitor-containing regimens",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "regimen"
                            }
                        },
                        {
                            "requirement_type": "BTK inhibitor approval status",
                            "expected_value": "approved as first line therapy"
                        },
                        {
                            "requirement_type": "phase",
                            "expected_value": "Phase 1"
                        }
                    ]
                },
                {
                    "exact_snippets": "with prior treatment defined by phase 2 cohort (Phase 2 Patients only)",
                    "criterion": "prior treatment as defined by phase 2 cohort",
                    "requirements": [
                        {
                            "requirement_type": "phase",
                            "expected_value": "Phase 2"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate hematologic function (Phase 1 and 1b Patients only).",
            "criterions": [
                {
                    "exact_snippets": "Adequate hematologic function (Phase 1 and 1b Patients only)",
                    "criterion": "hematologic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Responsive to transfusion support if given for thrombocytopenia or anemia (Phase 1 and 1b Patients only).",
            "criterions": [
                {
                    "exact_snippets": "Responsive to transfusion support if given for thrombocytopenia or anemia",
                    "criterion": "response to transfusion support",
                    "requirements": [
                        {
                            "requirement_type": "responsiveness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "thrombocytopenia",
                    "criterion": "thrombocytopenia",
                    "requirements": [
                        {
                            "requirement_type": "indication for transfusion support",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "anemia",
                    "criterion": "anemia",
                    "requirements": [
                        {
                            "requirement_type": "indication for transfusion support",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Phase 1 and 1b Patients only",
                    "criterion": "study phase",
                    "requirements": [
                        {
                            "requirement_type": "phase eligibility",
                            "expected_value": [
                                "Phase 1",
                                "Phase 1b"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically confirmed relapsed/recurrent CLL in whom venetoclax is appropriate standard salvage treatment; no prior venetoclax is permitted (Phase 1b Arm A Patients only).",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed relapsed/recurrent CLL",
                    "criterion": "chronic lymphocytic leukemia (CLL)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": "relapsed/recurrent CLL"
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "histologically confirmed"
                        }
                    ]
                },
                {
                    "exact_snippets": "venetoclax is appropriate standard salvage treatment",
                    "criterion": "venetoclax appropriateness",
                    "requirements": [
                        {
                            "requirement_type": "appropriateness for standard salvage treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "no prior venetoclax is permitted",
                    "criterion": "prior venetoclax treatment",
                    "requirements": [
                        {
                            "requirement_type": "prior exposure",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically confirmed relapsed/refractory CLL in whom venetoclax + rituximab is appropriate standard salvage treatment; no prior venetoclax is permitted (Phase 1b Arm B Patients only).",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed relapsed/refractory CLL",
                    "criterion": "chronic lymphocytic leukemia (CLL)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": "relapsed/refractory CLL"
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "histologically confirmed"
                        }
                    ]
                },
                {
                    "exact_snippets": "venetoclax + rituximab is appropriate standard salvage treatment",
                    "criterion": "appropriateness of venetoclax + rituximab as standard salvage treatment",
                    "requirements": [
                        {
                            "requirement_type": "appropriateness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "no prior venetoclax is permitted",
                    "criterion": "prior venetoclax treatment",
                    "requirements": [
                        {
                            "requirement_type": "history of prior treatment",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) 0-2.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) 0-2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate hepatic and renal function.",
            "criterions": [
                {
                    "exact_snippets": "Adequate hepatic ... function",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... renal function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability to receive study drug therapy orally.",
            "criterions": [
                {
                    "exact_snippets": "Ability to receive study drug therapy orally",
                    "criterion": "ability to receive study drug therapy orally",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willingness of men and women of reproductive potential (defined as following menarche and not postmenopausal [and 2 years of non-therapy-induced amenorrhea] or surgically sterile) to observe conventional and effective birth control.",
            "criterions": [
                {
                    "exact_snippets": "Willingness of men and women of reproductive potential ... to observe conventional and effective birth control.",
                    "criterion": "birth control use",
                    "requirements": [
                        {
                            "requirement_type": "willingness to use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "method type",
                            "expected_value": [
                                "conventional",
                                "effective"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "men and women of reproductive potential (defined as following menarche and not postmenopausal [and 2 years of non-therapy-induced amenorrhea] or surgically sterile)",
                    "criterion": "reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        },
                        {
                            "requirement_type": "menarche status",
                            "expected_value": "following menarche"
                        },
                        {
                            "requirement_type": "menopausal status",
                            "expected_value": "not postmenopausal"
                        },
                        {
                            "requirement_type": "amenorrhea duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "amenorrhea cause",
                            "expected_value": "non-therapy-induced"
                        },
                        {
                            "requirement_type": "surgical sterility",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Prior treatment with pirtobrutinib.",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with pirtobrutinib.",
                    "criterion": "prior treatment with pirtobrutinib",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any unresolved toxicities from prior therapy greater than CTCAE (version 5.0) Grade 2 or greater at the time of starting study treatment except for alopecia.",
            "criterions": [
                {
                    "exact_snippets": "Any unresolved toxicities from prior therapy greater than CTCAE (version 5.0) Grade 2 or greater at the time of starting study treatment",
                    "criterion": "unresolved toxicities from prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "CTCAE Grade"
                            }
                        },
                        {
                            "requirement_type": "resolution_status",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients requiring therapeutic anticoagulation with warfarin.",
            "criterions": [
                {
                    "exact_snippets": "Patients requiring therapeutic anticoagulation with warfarin",
                    "criterion": "therapeutic anticoagulation with warfarin",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For patients enrolled to phase 1b Arm A or B: Patients with prior treatment with venetoclax or other BCL-2 inhibitors.",
            "criterions": [
                {
                    "exact_snippets": "Patients with prior treatment with venetoclax or other BCL-2 inhibitors",
                    "criterion": "prior treatment with venetoclax or other BCL-2 inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have tested positive for human immunodeficiency virus (HIV) are excluded. For patients with unknown HIV status, HIV testing will be performed at Screening and result should be negative for enrollment.",
            "criterions": [
                {
                    "exact_snippets": "Patients who have tested positive for human immunodeficiency virus (HIV) are excluded",
                    "criterion": "HIV status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "For patients with unknown HIV status, HIV testing will be performed at Screening and result should be negative for enrollment",
                    "criterion": "HIV status",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Radiotherapy with a limited field of radiation for palliation within 7 days of the first dose of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Radiotherapy with a limited field of radiation for palliation within 7 days of the first dose of study treatment.",
                    "criterion": "radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "field size",
                            "expected_value": "limited"
                        },
                        {
                            "requirement_type": "purpose",
                            "expected_value": "palliation"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days from first dose of study treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active second malignancy unless in remission and with life expectancy > 2 years.",
            "criterions": [
                {
                    "exact_snippets": "Active second malignancy",
                    "criterion": "second malignancy",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unless in remission",
                    "criterion": "second malignancy remission status",
                    "requirements": [
                        {
                            "requirement_type": "remission",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "life expectancy > 2 years",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known hypersensitivity to any component or excipient of pirtobrutinib.",
            "criterions": [
                {
                    "exact_snippets": "Known hypersensitivity to any component or excipient of pirtobrutinib",
                    "criterion": "hypersensitivity to pirtobrutinib components or excipients",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with prior significant hypersensitivity to rituximab requiring discontinuation, prior allergic or anaphylactic reaction to rituximab (Phase 1b Arm B Patients only).",
            "criterions": [
                {
                    "exact_snippets": "prior significant hypersensitivity to rituximab requiring discontinuation",
                    "criterion": "hypersensitivity to rituximab",
                    "requirements": [
                        {
                            "requirement_type": "history of hypersensitivity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        },
                        {
                            "requirement_type": "consequence",
                            "expected_value": "requiring discontinuation"
                        }
                    ]
                },
                {
                    "exact_snippets": "prior allergic or anaphylactic reaction to rituximab (Phase 1b Arm B Patients only)",
                    "criterion": "allergic or anaphylactic reaction to rituximab",
                    "requirements": [
                        {
                            "requirement_type": "history of allergic or anaphylactic reaction",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "applicability",
                            "expected_value": "Phase 1b Arm B Patients only"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically significant, uncontrolled cardiac, cardiovascular disease or history of myocardial infarction within 6 months prior to planned start of pirtobrutinib.",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant, uncontrolled cardiac, cardiovascular disease",
                    "criterion": "cardiac or cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "history of myocardial infarction within 6 months prior to planned start of pirtobrutinib",
                    "criterion": "history of myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active uncontrolled systemic bacterial, viral, fungal or parasitic infection.",
            "criterions": [
                {
                    "exact_snippets": "Active uncontrolled systemic bacterial, viral, fungal or parasitic infection.",
                    "criterion": "systemic infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "bacterial",
                                "viral",
                                "fungal",
                                "parasitic"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnancy or lactation.",
            "criterions": [
                {
                    "exact_snippets": "Pregnancy",
                    "criterion": "pregnancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "lactation",
                    "criterion": "lactation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery within 4 weeks prior to planned start of specified study therapy.",
            "criterions": [
                {
                    "exact_snippets": "Major surgery within 4 weeks prior to planned start of specified study therapy.",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically significant active malabsorption syndrome.",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant active malabsorption syndrome",
                    "criterion": "malabsorption syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current treatment with certain strong CYP3A4 inhibitors or inducers and/or strong P-gp inhibitors.",
            "criterions": [
                {
                    "exact_snippets": "Current treatment with certain strong CYP3A4 inhibitors",
                    "criterion": "current treatment with strong CYP3A4 inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Current treatment with certain strong CYP3A4...inducers",
                    "criterion": "current treatment with strong CYP3A4 inducers",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Current treatment with...strong P-gp inhibitors",
                    "criterion": "current treatment with strong P-gp inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of allogeneic or autologous stem cell transplant (SCT) or chimeric antigen receptor-modified T-cell (CAR-T) therapy within the past 60 days (180 days before the PK trigger) prior to planned start of specified study therapy.",
            "criterions": [
                {
                    "exact_snippets": "History of allogeneic or autologous stem cell transplant (SCT) ... within the past 60 days (180 days before the PK trigger) prior to planned start of specified study therapy.",
                    "criterion": "stem cell transplant (SCT)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "allogeneic",
                                "autologous"
                            ]
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 60,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... chimeric antigen receptor-modified T-cell (CAR-T) therapy within the past 60 days (180 days before the PK trigger) prior to planned start of specified study therapy.",
                    "criterion": "CAR-T therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 60,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For patients enrolled to phase 1b Arm B: Patients with prior significant hypersensitivity, allergy, or anaphylactic reaction to rituximab/biosimilar requiring discontinuation.",
            "criterions": [
                {
                    "exact_snippets": "prior significant hypersensitivity, allergy, or anaphylactic reaction to rituximab/biosimilar requiring discontinuation",
                    "criterion": "hypersensitivity, allergy, or anaphylactic reaction to rituximab/biosimilar",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        },
                        {
                            "requirement_type": "consequence",
                            "expected_value": "requiring discontinuation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Investigational agent or anticancer therapy within 5 half-lives or 14 days, whichever is shorter, prior to planned start of specified study therapy except antineoplastic and immunosuppressant monoclonal antibody treatment must be discontinued a minimum of 4 weeks prior to the first dose of pirtobrutinib. In addition, no concurrent systemic anticancer therapy is permitted.",
            "criterions": [
                {
                    "exact_snippets": "Investigational agent or anticancer therapy within 5 half-lives or 14 days, whichever is shorter, prior to planned start of specified study therapy",
                    "criterion": "prior investigational agent or anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "washout period",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 14,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "antineoplastic and immunosuppressant monoclonal antibody treatment must be discontinued a minimum of 4 weeks prior to the first dose of pirtobrutinib",
                    "criterion": "prior antineoplastic and immunosuppressant monoclonal antibody treatment",
                    "requirements": [
                        {
                            "requirement_type": "washout period",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "no concurrent systemic anticancer therapy is permitted",
                    "criterion": "concurrent systemic anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "concurrent use",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active uncontrolled auto-immune cytopenia where new therapy introduced or concomitant therapy escalated within the 4 weeks prior to study enrollment is required to maintain adequate blood counts.",
            "criterions": [
                {
                    "exact_snippets": "Active uncontrolled auto-immune cytopenia",
                    "criterion": "auto-immune cytopenia",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "new therapy introduced ... within the 4 weeks prior to study enrollment",
                    "criterion": "new therapy for auto-immune cytopenia",
                    "requirements": [
                        {
                            "requirement_type": "introduction timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to study enrollment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "concomitant therapy escalated within the 4 weeks prior to study enrollment",
                    "criterion": "concomitant therapy escalation for auto-immune cytopenia",
                    "requirements": [
                        {
                            "requirement_type": "escalation timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to study enrollment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "required to maintain adequate blood counts",
                    "criterion": "requirement of therapy to maintain adequate blood counts",
                    "requirements": [
                        {
                            "requirement_type": "necessity for adequate blood counts",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known central nervous system (CNS) involvement by systemic lymphoma. Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of disease may be eligible and enrolled to phase 2 Cohort 7 if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval.",
            "criterions": [
                {
                    "exact_snippets": "Known central nervous system (CNS) involvement by systemic lymphoma.",
                    "criterion": "central nervous system (CNS) involvement by systemic lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of disease may be eligible ... if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval.",
                    "criterion": "previous treatment for CNS involvement",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "neurological stability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "evidence of disease",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "compelling clinical rationale by Investigator",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documented Sponsor approval",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}